Bristol-Myers Squibb (BMS) has signed a whopping $3.6 billion deal to pair its Opdivo and Yervoy with Nektar’s NKTR-214 in a range of tumor types. The two companies have agreed to co-develop NKTR-214 in combination with PD-1 antagonist Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) in more than 20 indications across nine cancers, including melanoma, renal cell carcinoma, non-small-cell lung cancer, bladder cancer and triple-negative breast cancer. Pivotal trials in RCC and mela...